It helps to start with what is actually known, rather than what gets repeated: the question of iv, im, sublingual or spravato: comparing the routes looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
In the United States the same rule applies: the phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. Where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. Applied to the United States, the point is this: asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause. That holds in the United States as it does everywhere: the subanaesthetic dose used in this work is a fraction of the surgical dose, which is why the person stays awake, breathing independently and able to communicate.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
What to do next
The honest summary is that the short-term findings are encouraging and the long-term picture remains genuinely unsettled. The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. Patients researching the United States providers run into this constantly. Using remote care to mail a dissociative anaesthetic to an unmonitored patient is a different proposition from using it for the consultation, and the distinction is worth insisting on. Nothing about the United States changes that. Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment. It is the first thing to establish about any the United States programme. Dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes.
The the United States comparison only becomes useful once this is clear. In 2023 the FDA issued a public warning about compounded ketamine products used at home without monitoring, citing risks including sedation, dissociation, airway compromise and the absence of any clinician present if something goes wrong. That warning is the clearest available signal about where the regulatory line sits. Telehealth has a legitimate and useful role in this field for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Using it to mail a dissociative anaesthetic to an unmonitored patient is a different proposition, and the distinction is worth insisting on.
How the pieces fit together in practice
The mechanism matters practically because it implies the days after a session may be unusually receptive to therapeutic work. Anyone comparing the United States programmes will find this decisive: ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. Asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. Weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. The population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials. That is as true in the United States as anywhere else in the country. Cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing. It is worth carrying that into every conversation with a the United States provider.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Safety, screening and the limits of the evidence
Integration, the structured work of making sense of a session afterwards, is the element most often missing from purely procedural clinics. The information gap in the United States is not about whether ketamine treatment exists locally but about how to tell two local programmes apart. The headline per-session price usually excludes the consultation, any separately billed psychiatric evaluation, integration therapy and the maintenance sessions that follow. Read against the the United States market, whether a programme titrates the dose according to response and tolerability, or runs a fixed protocol for everyone, is a meaningful difference in how individualised the care actually is. Randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require.
Every the United States programme is operating inside the same clinical framework, which runs as follows. Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
Money, timing and the logistics people underestimate
Each session occupies roughly two hours on site once administration, monitoring and recovery are counted, which is longer than most people budget for. A clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. The the United States listings on this page are organised so that this is checkable rather than assumed. Antagonism at the N-methyl-D-aspartate receptor appears to trigger a downstream cascade involving brain-derived neurotrophic factor and increased synaptic connectivity in mood-regulating regions. For anyone weighing options in the United States, the induction course is the part everyone discusses; what happens after it is the part that determines the real cost and the real commitment. The practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable.
The the United States comparison only becomes useful once this is clear. Cost is the constraint that decides the matter for a large share of people, and the numbers are rarely posted plainly. A single intravenous infusion in the United States commonly falls somewhere between four hundred and eight hundred dollars, which puts a six-session induction in the range of roughly two and a half to five thousand dollars before any maintenance. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable. Esketamine is a different story, since an approved indication makes coverage plausible, subject to prior authorisation and documented failure of prior treatments. Before committing to anything, it is worth asking for the total cost of the induction course, the cost of a maintenance session, whether the consultation is billed separately, and what happens financially if treatment is stopped partway through.
Why this question is harder than it should be
Ketamine work sits between psychiatric assessment and sedation management, and clinicians arrive at it from either side with correspondingly different instincts. Search results for ketamine treatment in the United States return a remarkably uniform set of pages, which makes genuine comparison harder rather than easier. A dose calculated against body weight and adjusted across a course reflects a different philosophy from one held constant regardless of what the previous session produced. It is the first thing to establish about any the United States programme. That holds in the United States as it does everywhere: travel time belongs in the treatment plan rather than being treated as a detail to solve later. Transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals. It is worth carrying that into every conversation with a the United States provider.
Esketamine, marketed as Spravato, occupies a different regulatory position that is routinely blurred in advertising. It is the S-enantiomer of ketamine, delivered as a nasal spray, and the FDA approved it in 2019 for treatment-resistant depression in adults used alongside an oral antidepressant, then in 2020 for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour. Because it carries a Risk Evaluation and Mitigation Strategy, it can only be given at certified treatment centres, the patient must be observed for at least two hours afterwards, and they cannot drive until the following day. That is the entire practical difference for most people: esketamine is approved, insurable more often than not, and inconvenient; generic intravenous ketamine is off-label, usually paid out of pocket, and more flexible in how it is dosed.
Putting this to use
In the United States the same rule applies: screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. Solid food is usually restricted for several hours beforehand, largely to limit nausea during administration. A programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed. Nothing about the United States changes that. Dissociation is the effect people ask about most: a sense of distance from the body, altered time perception and sometimes visual distortion, typically peaking partway through and resolving within half an hour of the infusion ending. That is as true in the United States as anywhere else in the country. Applied to the United States, the point is this: any programme presenting six sessions as a complete and finished treatment, without discussing maintenance, has described half of what is involved.
The point of laying all this out is not to argue for or against treatment. It is to make sure that whichever way the decision goes, it is made with the real numbers and the real caveats rather than the marketing version.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.